谢维纳潘特加化学放射治疗在头癌中负面塑造瘤免疫微环境
Charleen Chan Wah Hak1, Emmanuel C Patin1, Anton Patrikeev1
1Institute of Cancer Research, London, United Kingdom.
Cancer research communications
|October 22, 2025
概括
与化疗放射治疗 (CRT) 结合的xevinapant没有改善头癌的结果. 这种组合疗法对瘤微环境产生了免疫抑制作用,这可能解释了临床益处的缺乏.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 克西维纳潘特是一种口服生物可用抑制剂,是亡蛋白 (IAP) 家族的对手.
- 第二期试验显示,xevinapant在头部和部状细胞癌 (SCCHN) 中具有前景.
研究的目的:
- 研究xevinapant加化学放射治疗 (CRT) 对SCCHN中的瘤免疫微环境的影响.
- 了解TrilynXIII期试验中观察到的缺乏临床益处背后的机制.
主要方法:
- 使用了用xevinapant加CRT治疗的SCCHN免疫能力较强的小鼠模型.
- 分析了瘤透免疫细胞 (CD8+ T细胞,NK细胞) 和基因表达的变化.
- 评估了急性阶段蛋白质和亡媒介体 (RIPK3) 的水平.
主要成果:
- 在小鼠模型中,xevinapant加CRT维持或改善了局部区域控制,但独立于CD8+T细胞.
- 联合治疗减少了细胞毒性CD8+T细胞和NK细胞的透.
- 观察到免疫相关基因表达的减少,免疫调节蛋白的增加和RIPK3水平的降低.
结论:
- 克西维纳潘特加CRT对瘤免疫微环境产生免疫抑制作用.
- 这种免疫抑制可能解释xevinapant在SCCHN的TrilynX临床试验中未能改善结果.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
10.2K
相关概念视频
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
574
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
574
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
595
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
595
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
